| 1 | Fluorescent probes for monitoring myeloperoxidase-derived hypochlorous acid: a comparative study. (Pierzchała K, Pięta M, Rola M, Świerczyńska M, Artelska A, Dębowska K, Podsiadły R, Pięta J, Zielonka J, Sikora A, Marcinek A, Michalski R) Sci Rep 2022 Jun 03;12(1):9314 14 Citations |
| 1 | A Hyaluronan and Proteoglycan Link Protein 1 Matrikine: Role of Matrix Metalloproteinase 2 in Multiple Myeloma NF-κB Activation and Drug Resistance. (Mark C, Warrick J, Callander NS, Hematti P, Miyamoto S) Mol Cancer Res 2022 Sep 02;20(9):1456-1466 7 Citations |
| 1 | Novel Boronate Probe Based on 3-Benzothiazol-2-yl-7-hydroxy-chromen-2-one for the Detection of Peroxynitrite and Hypochlorite. (Modrzejewska J, Szala M, Grzelakowska A, Zakłos-Szyda M, Zielonka J, Podsiadły R) Molecules 2021 Sep 30;26(19) 11 Citations |
| 3 | Identification of Peroxynitrite by Profiling Oxidation and Nitration Products from Mitochondria-Targeted Arylboronic Acid. (Zielonka J, Sikora A, Podsiadly R, Hardy M, Kalyanaraman B) Methods Mol Biol 2021;2275:315-327 10 Citations |
| 1 | Potent Inhibition of Mandelate Racemase by Boronic Acids: Boron as a Mimic of a Carbon Acid Center. (Sharma AN, Grandinetti L, Johnson ER, St Maurice M, Bearne SL) Biochemistry 2020 Aug 25;59(33):3026-3037 8 Citations |
| 2 | Tracking isotopically labeled oxidants using boronate-based redox probes. (Rios N, Radi R, Kalyanaraman B, Zielonka J) J Biol Chem 2020 May 08;295(19):6665-6676 18 Citations |
| 1 | Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. (Falchook G, Rosen S, LoRusso P, Watts J, Gupta S, Coombs CC, Talpaz M, Kurzrock R, Mita M, Cassaday R, Harb W, Peguero J, Smith DC, Piha-Paul SA, Szmulewitz R, Noel MS, Yeleswaram S, Liu P, Switzky J, Zhou G, Zheng F, Mehta A) Clin Cancer Res 2020 Mar 15;26(6):1247-1257 63 Citations |
| 1 | Discovery and Optimization of Novel Hydrogen Peroxide Activated Aromatic Nitrogen Mustard Derivatives as Highly Potent Anticancer Agents. (Chen W, Fan H, Balakrishnan K, Wang Y, Sun H, Fan Y, Gandhi V, Arnold LA, Peng X) J Med Chem 2018 Oct 25;61(20):9132-9145 46 Citations |
| 1 | Hydrogen peroxide activated quinone methide precursors with enhanced DNA cross-linking capability and cytotoxicity towards cancer cells. (Wang Y, Fan H, Balakrishnan K, Lin Z, Cao S, Chen W, Fan Y, Guthrie QA, Sun H, Teske KA, Gandhi V, Arnold LA, Peng X) Eur J Med Chem 2017 Jun 16;133:197-207 27 Citations |
| 1 | Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma. (Vogl DT, Martin TG, Vij R, Hari P, Mikhael JR, Siegel D, Wu KL, Delforge M, Gasparetto C) Leuk Lymphoma 2017 Aug;58(8):1872-1879 58 Citations |
| 1 | NADPH Oxidase-Derived Peroxynitrite Drives Inflammation in Mice and Human Nonalcoholic Steatohepatitis via TLR4-Lipid Raft Recruitment. (Das S, Alhasson F, Dattaroy D, Pourhoseini S, Seth RK, Nagarkatti M, Nagarkatti PS, Michelotti GA, Diehl AM, Kalyanaraman B, Chatterjee S) Am J Pathol 2015 Jul;185(7):1944-57 42 Citations |
| 1 | A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study. (Horton TM, Drachtman RA, Chen L, Cole PD, McCarten K, Voss S, Guillerman RP, Buxton A, Howard SC, Hogan SM, Sheehan AM, López-Terrada D, Mrazek MD, Agrawal N, Wu MF, Liu H, De Alarcon PA, Trippet TM, Schwartz CL) Br J Haematol 2015 Jul;170(1):118-22 24 Citations |
| 2 | Detection and differentiation between peroxynitrite and hydroperoxides using mitochondria-targeted arylboronic acid. (Zielonka J, Sikora A, Adamus J, Kalyanaraman B) Methods Mol Biol 2015;1264:171-81 28 Citations |
| 2 | Nitroxyl (HNO) reacts with molecular oxygen and forms peroxynitrite at physiological pH. Biological Implications. (Smulik R, Dębski D, Zielonka J, Michałowski B, Adamus J, Marcinek A, Kalyanaraman B, Sikora A) J Biol Chem 2014 Dec 19;289(51):35570-81 66 Citations |
| 1 | Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. (Falchook GS, Wheler JJ, Naing A, Jackson EF, Janku F, Hong D, Ng CS, Tannir NM, Lawhorn KN, Huang M, Angelo LS, Vishwamitra D, Hess K, Howard AN, Parkhurst KL, Amin HM, Kurzrock R) Oncotarget 2014 Nov 15;5(21):10280-92 53 Citations |
| 1 | Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network. (Callander N, Markovina S, Eickhoff J, Hutson P, Campbell T, Hematti P, Go R, Hegeman R, Longo W, Williams E, Asimakopoulos F, Miyamoto S) Cancer Chemother Pharmacol 2014 Oct;74(4):875-82 31 Citations |
| 1 | Bortezomib for refractory autoimmunity in pediatrics. (Khandelwal P, Davies SM, Grimley MS, Jordan MB, Curtis BR, Jodele S, Marsh R, Filipovich AH) Biol Blood Marrow Transplant 2014 Oct;20(10):1654-9 43 Citations |
| 2 | Real-time measurements of amino acid and protein hydroperoxides using coumarin boronic acid. (Michalski R, Zielonka J, Gapys E, Marcinek A, Joseph J, Kalyanaraman B) J Biol Chem 2014 Aug 08;289(32):22536-53 63 Citations |
| 1 | Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). (Jaccard A, Comenzo RL, Hari P, Hawkins PN, Roussel M, Morel P, Macro M, Pellegrin JL, Lazaro E, Mohty D, Mercie P, Decaux O, Gillmore J, Lavergne D, Bridoux F, Wechalekar AD, Venner CP) Haematologica 2014 Sep;99(9):1479-85 112 Citations |
| 2 | Inducible nitric oxide synthase is key to peroxynitrite-mediated, LPS-induced protein radical formation in murine microglial BV2 cells. (Kumar A, Chen SH, Kadiiska MB, Hong JS, Zielonka J, Kalyanaraman B, Mason RP) Free Radic Biol Med 2014 Aug;73:51-9 77 Citations |
| 1 | Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population. (Wheler J, Falchook G, Tsimberidou AM, Hong D, Naing A, Piha-Paul S, Chen SS, Heymach J, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R) Oncotarget 2013 May;4(5):772-84 19 Citations |
| 2 | Real-time monitoring of reactive oxygen and nitrogen species in a multiwell plate using the diagnostic marker products of specific probes. (Zielonka J, Joseph J, Sikora A, Kalyanaraman B) Methods Enzymol 2013;526:145-57 23 Citations |
| 2 | Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF. (Chaudhary L, Awan F, Cumpston A, Leadmon S, Watkins K, Tse W, Craig M, Hamadani M) J Clin Apher 2013 Oct;28(5):359-67 28 Citations |
| 1 | Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study. (Hoang T, Campbell TC, Zhang C, Kim K, Kolesar JM, Oettel KR, Blank JH, Robinson EG, Ahuja HG, Kirschling RJ, Johnson PH, Huie MS, Wims ME, Larson MM, Hernan HR, Traynor AM) Invest New Drugs 2014 Feb;32(1):195-9 36 Citations |
| 1 | Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib. (Stessman HA, Mansoor A, Zhan F, Janz S, Linden MA, Baughn LB, Van Ness B) Leukemia 2013 Oct;27(10):2075-7 44 Citations |
| 2 | Reaction between peroxynitrite and triphenylphosphonium-substituted arylboronic acid isomers: identification of diagnostic marker products and biological implications. (Sikora A, Zielonka J, Adamus J, Debski D, Dybala-Defratyka A, Michalowski B, Joseph J, Hartley RC, Murphy MP, Kalyanaraman B) Chem Res Toxicol 2013 Jun 17;26(6):856-67 42 Citations |
| 1 | Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. (Stessman HA, Baughn LB, Sarver A, Xia T, Deshpande R, Mansoor A, Walsh SA, Sunderland JJ, Dolloff NG, Linden MA, Zhan F, Janz S, Myers CL, Van Ness BG) Mol Cancer Ther 2013 Jun;12(6):1140-50 62 Citations |
| 1 | Bioluminescent detection of peroxynitrite with a boronic acid-caged luciferin. (Sieracki NA, Gantner BN, Mao M, Horner JH, Ye RD, Malik AB, Newcomb ME, Bonini MG) Free Radic Biol Med 2013 Aug;61:40-50 39 Citations |
| 3 | Boronate probes as diagnostic tools for real time monitoring of peroxynitrite and hydroperoxides. (Zielonka J, Sikora A, Hardy M, Joseph J, Dranka BP, Kalyanaraman B) Chem Res Toxicol 2012 Sep 17;25(9):1793-9 203 Citations |
| 1 | Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells. (Kim J, Denu RA, Dollar BA, Escalante LE, Kuether JP, Callander NS, Asimakopoulos F, Hematti P) Br J Haematol 2012 Aug;158(3):336-46 106 Citations |
| 1 | Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. (Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, Stewart AK, Turturro F, Rifkin R, Wolf J, Estevam J, Mulligan G, Shi H, Webb IJ, Rajkumar SV) Blood 2012 May 10;119(19):4375-82 399 Citations |
| 1 | Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies. (Falchook GS, Duvic M, Hong DS, Wheler J, Naing A, Lim J, Kurzrock R) Cancer Chemother Pharmacol 2012 May;69(5):1117-26 16 Citations |
| 1 | Oxidative chemistry of fluorescent dyes: implications in the detection of reactive oxygen and nitrogen species. (Kalyanaraman B) Biochem Soc Trans 2011 Oct;39(5):1221-5 66 Citations |
| 1 | An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. (Atkinson JM, Shelat AA, Carcaboso AM, Kranenburg TA, Arnold LA, Boulos N, Wright K, Johnson RA, Poppleton H, Mohankumar KM, Féau C, Phoenix T, Gibson P, Zhu L, Tong Y, Eden C, Ellison DW, Priebe W, Koul D, Yung WK, Gajjar A, Stewart CF, Guy RK, Gilbertson RJ) Cancer Cell 2011 Sep 13;20(3):384-99 94 Citations |
| 1 | Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies. (Lee EC, Fitzgerald M, Bannerman B, Donelan J, Bano K, Terkelsen J, Bradley DP, Subakan O, Silva MD, Liu R, Pickard M, Li Z, Tayber O, Li P, Hales P, Carsillo M, Neppalli VT, Berger AJ, Kupperman E, Manfredi M, Bolen JB, Van Ness B, Janz S) Clin Cancer Res 2011 Dec 01;17(23):7313-23 94 Citations |
| 1 | VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. (Chang JE, Peterson C, Choi S, Eickhoff JC, Kim K, Yang DT, Gilbert LA, Rogers ES, Werndli JE, Huie MS, McFarland TA, Volk M, Blank J, Callander NS, Longo WL, Kahl BS) Br J Haematol 2011 Oct;155(2):190-7 51 Citations |
| 2 | Reaction between peroxynitrite and boronates: EPR spin-trapping, HPLC Analyses, and quantum mechanical study of the free radical pathway. (Sikora A, Zielonka J, Lopez M, Dybala-Defratyka A, Joseph J, Marcinek A, Kalyanaraman B) Chem Res Toxicol 2011 May 16;24(5):687-97 88 Citations |
| 1 | Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation. (Awan FT, Osman S, Kochuparambil ST, Gibson L, Remick SC, Abraham J, Craig M, Jillella A, Hamadani M) Bone Marrow Transplant 2012 Jan;47(1):146-8 5 Citations |
| 1 | High immunologic risk living donor kidney transplant using bortezomib in a novel induction regimen without acute antibody mediated rejection. (Dunn TB, Borja-Cacho D, Chinnakotla S, Finger E, Tamayo G, Verghese P, Kim Y, Manivel C, Kandaswamy R, Matas A, Pruett T, Noreen H, Krefting P, Maurer D) Clin Transpl 2011:381-7 2 Citations |
| 1 | Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells. (Markovina S, Callander NS, O'Connor SL, Xu G, Shi Y, Leith CP, Kim K, Trivedi P, Kim J, Hematti P, Miyamoto S) Mol Cancer 2010 Jul 06;9:176 99 Citations |
| 1 | Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors. (Subbiah V, Trent JC, Kurzrock R) J Clin Oncol 2010 Aug 20;28(24):e415 48 Citations |
| 1 | Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. (Kumar SK, Flinn I, Noga SJ, Hari P, Rifkin R, Callander N, Bhandari M, Wolf JL, Gasparetto C, Krishnan A, Grosman D, Glass J, Sahovic EA, Shi H, Webb IJ, Richardson PG, Rajkumar SV) Leukemia 2010 Jul;24(7):1350-6 77 Citations |
| 2 | Peroxynitrite is the major species formed from different flux ratios of co-generated nitric oxide and superoxide: direct reaction with boronate-based fluorescent probe. (Zielonka J, Sikora A, Joseph J, Kalyanaraman B) J Biol Chem 2010 May 07;285(19):14210-6 181 Citations |
| 1 | Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma. (Benson DM Jr, Panzner K, Hamadani M, Hofmeister CC, Bakan CE, Smith MK, Elder P, Krugh D, O'Donnell L, Devine SM) Leuk Lymphoma 2010 Feb;51(2):243-51 15 Citations |
| 2 | Direct oxidation of boronates by peroxynitrite: mechanism and implications in fluorescence imaging of peroxynitrite. (Sikora A, Zielonka J, Lopez M, Joseph J, Kalyanaraman B) Free Radic Biol Med 2009 Nov 15;47(10):1401-7 305 Citations |
| 1 | Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. (Giralt S, Vesole DH, Somlo G, Krishnan A, Stadtmauer E, Mccarthy P, Pasquini MC, Blood and Marrow Transplant Clinical Trials Network Multiple Myeloma Working Group) J Natl Cancer Inst 2009 Jul 01;101(13):964; author reply 966-7 9 Citations |
| 1 | A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer. (LoConte NK, Thomas JP, Alberti D, Heideman J, Binger K, Marnocha R, Utecht K, Geiger P, Eickhoff J, Wilding G, Kolesar J) Cancer Chemother Pharmacol 2008 Dec;63(1):109-15 18 Citations |
| 1 | Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. (Mukherjee S, Raje N, Schoonmaker JA, Liu JC, Hideshima T, Wein MN, Jones DC, Vallet S, Bouxsein ML, Pozzi S, Chhetri S, Seo YD, Aronson JP, Patel C, Fulciniti M, Purton LE, Glimcher LH, Lian JB, Stein G, Anderson KC, Scadden DT) J Clin Invest 2008 Feb;118(2):491-504 221 Citations |
| 1 | Multiple myeloma: charging toward a bright future. (Katzel JA, Hari P, Vesole DH) CA Cancer J Clin 2007;57(5):301-18 93 Citations |
| 1 | Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. (Khanbolooki S, Nawrocki ST, Arumugam T, Andtbacka R, Pino MS, Kurzrock R, Logsdon CD, Abbruzzese JL, McConkey DJ) Mol Cancer Ther 2006 Sep;5(9):2251-60 125 Citations |
| 2 | NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. (Vodanovic-Jankovic S, Hari P, Jacobs P, Komorowski R, Drobyski WR) Blood 2006 Jan 15;107(2):827-34 107 Citations |
| 1 | A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. (Dy GK, Thomas JP, Wilding G, Bruzek L, Mandrekar S, Erlichman C, Alberti D, Binger K, Pitot HC, Alberts SR, Hanson LJ, Marnocha R, Tutsch K, Kaufmann SH, Adjei AA) Clin Cancer Res 2005 May 01;11(9):3410-6 66 Citations |
| 1 | Function of nuclear factor kappaB in pancreatic cancer metastasis. (Fujioka S, Sclabas GM, Schmidt C, Frederick WA, Dong QG, Abbruzzese JL, Evans DB, Baker C, Chiao PJ) Clin Cancer Res 2003 Jan;9(1):346-54 214 Citations |
| 1 | The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. (Dong QG, Sclabas GM, Fujioka S, Schmidt C, Peng B, Wu T, Tsao MS, Evans DB, Abbruzzese JL, McDonnell TJ, Chiao PJ) Oncogene 2002 Sep 19;21(42):6510-9 158 Citations |
